Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs PXL 770 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Poxel
  • Most Recent Events

    • 30 Aug 2018 According to a Poxel media release, the company expects to initiate this study in 2019.
    • 18 Jul 2018 According to an Poxel media release, in second half of 2018, company will under go the preparation of this study, which includes, an IND application to the US FDA, manufacturing of drug product and validation of clinical sites.
    • 25 Jan 2018 According to an Poxel media release, this trial is expected to initiate during the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top